Skip to main content
. 2026 Sep 24;14(10):2161. doi: 10.3390/biomedicines14102161
CTCs Circulating tumor cells
PD-L1 programmed cell death-ligand 1
EVs extracellular vesicles
NSCLC non-small cell lung cancer
SCLC small cell lung cancer
ORR objective response rate
PD Disease progression
SD Stable disease
PR Partial response
ROC receiver operating characteristic curves
WES whole-exome sequencing
ICIs immune checkpoint inhibitors
TMB tumor mutation burden
AUC area under the curve
PFS progression-free survival